Research programme: cytomegalovirus infection antivirals - INAGEN
Latest Information Update: 16 Jul 2016
At a glance
- Originator INAGEN
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Denmark
- 18 Dec 2008 Preclinical trials in Cytomegalovirus infections in Denmark (unspecified route)